Introduction
============

ALI[@b1-dddt-11-1233] is caused by a thrombotic and/or embolic occlusion of a peripheral vessel.[@b1-dddt-11-1233] Patients with ALI represent a high-risk cohort[@b2-dddt-11-1233] in need of complex revascularization procedures that are often associated with a significant rate of periinterventional complications.

The consequences of ALI such as prolonged hospitalization, major limb amputation, and/or death have a profound socioeconomic impact worldwide. Recently, it has been shown that in a 1-year follow-up, limb loss occurs in 10%--70% of all ALI cases, depending on the Rutherford categories. In addition, mortality following acute low-extremity ischemia reaches up to 15%;[@b1-dddt-11-1233] unfortunately, these numbers have not improved over the years.[@b3-dddt-11-1233]

Hence, development of new treatment options and better management of ALI is an urgent need in clinical everyday life. During the past decades, interventional treatment of acute CLI such as low-dose targeted streptokinase treatment has proven to be an attractive alternative to surgical procedures.[@b4-dddt-11-1233],[@b5-dddt-11-1233] Three different multicenter trials have compared thrombolysis with surgical treatment so far: the Rochester study,[@b6-dddt-11-1233] the STILE trial (Surgery versus Thrombolysis for Ischemic Lower Extremity) conducted in 1994,[@b7-dddt-11-1233] and the TOPAS (Thrombolysis Or Peripheral Arterial Surgery) trial conducted in 1996.[@b8-dddt-11-1233] Based on their convincing results, catheter-based thrombolysis emerged as a first-line therapy of ALI and is preferred to surgery unless there are absolute thrombolysis contraindications.[@b4-dddt-11-1233]

Meanwhile, additional treatment options such as different percutaneous mechanical thrombectomy devices have emerged.[@b9-dddt-11-1233],[@b10-dddt-11-1233] A very frequently used treatment option that has gained popularity in interventional practice is the Rotarex^®^ device (Straub Medical AG, Straubstrasse, Switzerland) that combines thrombus fragmentation and suction, and thus minimizes the hazard of peripheral embolizations.

Despite the high variety of different techniques available on the market, a systematical evaluation of the advantages and disadvantages of mechanical thrombectomy compared to classical thrombolysis therapy is still lacking. The current study aimed to compare safety and efficacy of mechanical thrombectomy, local thrombolysis treatment, and the combination of both during a 12-month follow-up based on a collective of 202 patients from the Heidelberg registry for peripheral artery disease.

Patients and methods
====================

Study design
------------

The current investigation is a non-randomized, retrospective single-center study. A total of 202 patients with acute and subacute thrombotic occlusions of the lower extremity, followed by a CLI, were enrolled between 2006 and 2015 at the Department of Cardiology, Angiology and Pneumology, University Hospital Heidelberg. Follow-up examinations (clinical visit, ABI, color duplex sonography) were performed immediately after, as well as 1, 3, 6, and 12 months after intervention. The study was approved by the local ethics committee at the University Hospital Heidelberg as a part of the Heidelberg registry for peripheral artery disease (S-331/2013). Informed consent was waived by the local ethics committee due to the retrospective design of the study, and provided that only the attending physicians were allowed to assess non-anonymized patient data.

The registry data were collected in accordance with the Declaration of Helsinki.

Interventional treatment methods
--------------------------------

All patients received a bolus of 2.500 U of heparin after placement of a 6F sheath introducer in the femoral artery. During intervention, all patients additionally received heparin to reach an activated clotting time of 250 seconds. If balloon dilatation and/or stent implantation was indicated, patients received 500 mg aspirin during and 300 mg clopidogrel after the intervention.

Out of 202 patients, 146 received primary treatment with the Rotarex^®^ device, 28 underwent thrombolysis, and 28 patients received a combination of Rotarex^®^ + thrombolysis. The type of intervention was selected by the interventionalist after angiography of the occluded lower limb, depending on the extension of the occlusion and the availability of the Rotarex^®^ system.

For local thrombolysis, a bolus of 10 mg rtPA was given after placing the local thrombolysis catheter (Cragg-McNamara, Ev3 Endovascular Inc., Plymouth, MN, USA) inside the thrombotic occlusion. Periinterventionally, rtPA was continuously administered (rate: 1 mg/h) for 18 hours in addition to heparin (target partial thromboplastin time of 60--80 seconds).

For rotational thrombectomy, an angiogram was performed, beginning at the proximal part of the common iliac artery and continuing down to the feet arteries. After placing the Rotarex^®^ wire through the thrombotic occlusion, the rotational thrombectomy device was slowly advanced and retracted in order to avoid embolic complications downstream of the occlusion. If necessary, the procedure was repeated until the blood flow was fully restored.

If indicated, a PTA and stent implantation was performed upon thrombus removal.

### Statistical analysis

Chi-square tests were used to compare categorical data. Continuous variables were represented as mean ± standard deviation. Analysis of variance was used to compare means when variables were normally distributed. Kaplan--Meier curves were drawn to present survival data, and log-rank tests were used to assess differences in time-to-event end points. A nonparametric (Kruskal--Wallis) test was used to compare the mean duration of hospital stay between the different groups. *P*-values of \<0.05 were considered statistically significant. Since no adjustment for multiplicity was performed, all *P*-values need to be interpreted descriptively, and in case of missing data, a complete-case analysis was performed. Data analysis was executed using GraphPad (Version 6.0) and SPSS (Version 22.0) software.

Results
=======

Complex lesion morphology and patient characteristics in a tertiary hospital collective
---------------------------------------------------------------------------------------

A total of 202 consecutive patients underwent a revascularization procedure upon thrombotic occlusion of the peripheral arteries between 2006 and 2015 at the University Hospital Heidelberg. Twenty-six out of 202 patients included in the study were critically ill with the following leading diagnoses: severe sepsis (n=7), acute cardiac failure (n=5), acute coronary syndrome (n=7), pulmonary embolism (n=3), acute-on-chronic renal failure (n=3), or stroke (n=1). Mean age in the Rotarex^®^-, thrombolysis-, and Rotarex^®^ plus thrombolysis-treated group was 67.5±11.4, 61.5±14.3, and 72.5±9.7 years, respectively. Demographic data regarding the patients' collective as well as relevant cardiovascular comorbidities are summarized in [Tables 1](#t1-dddt-11-1233){ref-type="table"} and [2](#t2-dddt-11-1233){ref-type="table"}. Duration of symptoms prior to hospitalization was less than 2 weeks in 34% of the Rotarex^®^, 54% of the thrombolysis, and 46% of the Rotarex^®^ plus thrombolysis group.

Target lesion characterization was performed by two independent examiners based on major angiographic features: calcification, degree of thrombotic occlusion, as well as length of occlusion. Low calcification grade was defined as no or only isolated plaques as previously described;[@b11-dddt-11-1233] up to 50% calcification was defined as moderate, and \>50% was referred to as severe.

The majority of patients displayed severe thrombotic burden: 67% (Rotarex^®^ group), 71% (thrombolysis group), and 89% (Rotarex^®^ plus thrombolysis group). In contrast, the grade of lesion calcification was low, whereas the vast majority of thrombotic occlusions treated in the study extended over a length of more than 10 cm in all three groups (*P*\>0.05, [Table 3](#t3-dddt-11-1233){ref-type="table"}).

The described interventions took place predominantly on native vessels (Rotarex^®^: 68.5%, thrombolysis: 78.6%, and Rotarex^®^ + thrombolysis: 71.4%). In addition to thrombectomy and/or thrombolysis, the rate of additional PTA did not differ between the three interventional groups (*P*\>0.05, [Table 3](#t3-dddt-11-1233){ref-type="table"}). No difference was seen for the number of stent implantations after thrombectomy and/or thrombolysis between the groups either ([Table 3](#t3-dddt-11-1233){ref-type="table"}). The exact target lesion localizations are represented in [Table 4](#t4-dddt-11-1233){ref-type="table"} which shows significantly more interventions in the SFA in the Rotarex^®^ vs thrombolysis group (*P*\<0.01).

Safety and efficacy of interventional treatment in the prevention of major end points
-------------------------------------------------------------------------------------

For evaluation of overall survival, patients were additionally subdivided into two groups: critically ill in-hospital patients (26 out of 202) where limb ischemia occurred as a complication of a primary systemic disease, and noncritically ill patients (176 out of 202) who had been admitted with the leading symptom of lower-extremity ALI. Kaplan--Meier analysis was performed in order to trace overall and amputation-free survival during a 1 year follow-up ([Figure 1A--D](#f1-dddt-11-1233){ref-type="fig"}). Overall survival 12 months after intervention was 96.02% in noncritically ill and 65% in critically ill patients. A total of 16 patients died during the follow-up due to septic shock (n=5), cardiogenic shock (n=4), asystole (n=1), electromechanical decoupling (n=1), major stroke (n=1), and cancer (n=1); in three patients, no information regarding the specific cause of death was available. Revascularization failure leading to amputation occurred in only three (1.5%) out of 202 patients. More specifically, one patient had a severe bleeding from the puncture site leading to surgical hematoma removal. Due to interruption of anticoagulation during the surgery, a subsequent total bypass re-occlusion occurred and a major amputation had to be performed. The second patient developed a fulminant phlegmone and was referred to surgery for urgent wound debridement resulting in a limb loss. The third patient refused a second intervention, although a major thrombotic residue upon primary thrombolysis was diagnosed.

By further evaluating the complication rate between the groups, our study demonstrated that Rotarex^®^-treated patients showed a significantly lower rate of major bleeding vs thrombolysis-treated ones ((non)critically ill, *P*\<0.05, [Table 5](#t5-dddt-11-1233){ref-type="table"}). Out of all patients with a relevant bleeding, a surgical hematoma removal was necessary only once; no bleeding-related death events were observed. Local vascular complications, such as pseudoaneurysm and/or arteriovenous fistula, occurred in one case each ([Table 5](#t5-dddt-11-1233){ref-type="table"}), and one patient in the Rotarex^®^ plus thrombolysis group developed a compartment syndrome that required further surgical treatment. The mean duration of hospital stay in the Rotarex^®^ group was significantly reduced in comparison to the two other groups of noncritically ill patients (*P*\<0.001, [Table 5](#t5-dddt-11-1233){ref-type="table"}).

High primary revascularization rates associated with interventional treatment of ALI
------------------------------------------------------------------------------------

Primary revascularization success immediately upon procedure was observed in the vast majority of all cases: \>98%. In terms of primary patency, the study showed that the Rotarex^®^-treated group was significantly better than both the thrombolysis and Rotarex^®^ plus thrombolysis group (*P*\<0.0001). In line with this was also the secondary patency rate upon mechanical thrombectomy (85%) showing less re-interventions compared both to thrombolysis and to combined therapy 12 months after primary revascularization (*P*\<0.05, [Figure 2A and B](#f2-dddt-11-1233){ref-type="fig"}). Examples of typical lesions treated with Rotarex^®^ are shown in [Figures S1](#SD1-dddt-11-1233){ref-type="supplementary-material"} and [S2](#SD2-dddt-11-1233){ref-type="supplementary-material"}.

Another important issue to address is whether differences in the duration of symptoms might have an impact on patients' outcome. The study demonstrated that the assessment of patients with acute (\<2 weeks) vs subacute (2--4 weeks) presentation of symptoms did not reveal any significant differences in terms of patency and/or amputation-free survival (data not shown).

Substantial ABI improvement upon intervention in all groups
-----------------------------------------------------------

Prior to intervention, all three patient groups presented severely reduced ABI values: 0.36±0.28. Immediately after intervention, the ABI values improved markedly in all three groups (Rotarex^®^ 0.87±0.23, Rotarex^®^ + thrombolysis 0.88±0.28, thrombolysis 0.71±0.31, *P*\>0.05) and remained stable over the next 12 months ([Figure 3](#f3-dddt-11-1233){ref-type="fig"} and [Table S1](#SD3-dddt-11-1233){ref-type="supplementary-material"}).

Discussion
==========

Epidemiological studies based on large populations show that ALI is a severe diagnosis and an independent predictor of both major amputation and mortality.[@b2-dddt-11-1233] Interventional methods for ALI treatment have been undergoing significant technical development over the last years. The Straub-Rotarex^®^ catheter has been widely used as a common alternative to local thrombolysis for more than a decade now,[@b12-dddt-11-1233] and different trials have pointed out the strengths of a catheter-guided rotational thrombectomy so far.[@b13-dddt-11-1233]--[@b16-dddt-11-1233] To the best of our knowledge, this is the first trial comparing Rotarex^®^ mechanical thrombectomy with the classical thrombolysis therapy, and the combination of both, in patients with ALI.

Previously published data of a single-arm study by Zeller et al demonstrated excellent primary revascularization success rates (92%) over a period of 12 months upon Rotarex^®^ treatment in a cohort of 98 ALI patients.[@b12-dddt-11-1233] However, this study also revealed a significant restenosis rate of up to 33% in native vessels, 74% in in-stent re-stenosis, and 86% in bypass graft occlusions.[@b12-dddt-11-1233] Three percent of all patients underwent amputation, and one patient died during follow-up. Wissgott et al investigated (sub)acute bypass occlusions in 20 patients and achieved complete thrombus removal in 90% of all cases[@b17-dddt-11-1233] using the Rotarex^®^ device or thrombolysis. One patient needed a re-intervention, and one suffered a major bleeding due to introducer sheath dislocation, followed by operative hematoma removal; there were no death events reported. Another study in 2001 by Bérczi et al followed up on 18 patients treated with the Rotarex^®^ thrombectomy device.[@b18-dddt-11-1233] The primary procedural success was 94%; however, the authors reported a high complication rate of 31.5%, including perforation and peripheral embolization. Primary and secondary patency 12 months after revascularization was 39% and 53%, respectively; there were no amputations or death events. In our cohort, primary revascularization success was observed in the vast majority of all cases (\>98%), which was comparable to the results of previous trials.[@b12-dddt-11-1233],[@b18-dddt-11-1233],[@b19-dddt-11-1233] Generally, our collective of 202 patients was characterized by a substantial heterogeneity. Patients who are admitted to the hospital with the leading and often single diagnosis of ALI (defined as noncritically ill) have a different starting point, a better perspective, and often a better outcome than critically ill patients, where ALI usually occurs in the context of multiple-organ failure, disseminated intravasal coagulopathy, severe sepsis, and/or shock. The differentiation between critically ill and noncritically ill patients in our study helps to illustrate that most of the periinterventional complications (eg, prolonged bleedings, amputation, and/or death) take place in the group of critically ill patients; this needs to be addressed and taken into consideration when assessing the general outcome after such an intervention. Indeed, major complications occurred in 19 cases during a follow-up of 12 months: a total of three amputations and 16 death cases, predominantly in critically ill patients.

However, the overall results of our trial remain unchanged despite the substantial number of critically ill patients enrolled in comparison to existing studies. In contrast, Zeller et al[@b12-dddt-11-1233] reported cardiogenic shock in one patient, Wissgott et al[@b17-dddt-11-1233] excluded patients with more advanced lesions (acute ischemia in stage III) or multiple lesions in their study, and Stanek et al[@b20-dddt-11-1233] reported about 40 patients with the leading diagnosis of peripheral arterial thromboembolic occlusions who were admitted selectively for revascularization. Thus, despite the high proportion (13%) of critically ill patients enrolled, and the high thrombotic burden in most cases, periinterventional success remains comparable to the results of previous trials.

Direct comparison between different interventional techniques in the current study demonstrated that the rate of major bleedings was significantly lower in Rotarex^®^-treated patients than in those receiving thrombolysis. Moreover, duration of hospitalization was also significantly prolonged in noncritically ill patients who underwent local thrombolysis therapy, also bearing more procedure-related costs. Thus, mechanical thrombectomy by Rotarex^®^ vs other treatment options provides advantages in terms of safety, shorter duration of hospitalizations, and lower costs.

In addition, mechanical thrombectomy was associated with a better outcome in terms of primary (\>63%) and secondary patency (\>85%) than thrombolysis alone and a combination of both. However, this result needs to be set into perspective against the predominant type of target lesions in the three treatment groups.

We cannot rule out lesion localization as a confounder, since the number of SFA revascularizations was highest in the Rotarex^®^ group and SFA lesions are generally more easily accessible than more distal occlusions in smaller arteries below the knee.

Strengths and limitations
-------------------------

As a retrospective analysis, the current study contains certain known limitations. In addition, the number of patients is limited, especially the group of critically ill patients, and thus, the results regarding the major end points need to be interpreted with caution.

Conclusion
==========

The current study provides a first rationale comparison between frequently applied interventional methods for the treatment of (sub)acute lower-extremity ischemia. Rotarex^®^--mechanical thrombectomy was not inferior to local thrombolysis and was associated with a lower complication rate, shorter duration of hospitalizations, and lower costs in a 12-month follow-up in a tertiary hospital collective. Further prospective randomized controlled trials are necessary to evaluate the results of the study.

Supplementary materials
=======================

###### 

A typical example of an acute thrombotic occlusion of the popliteal artery (**A**), insertion and advancement of the Rotarex^®^ device (**B**), PTA (**C**), and final revascularization angiogram following the successful mechanical thrombectomy (**D**).

**Abbreviation:** PTA, percutaneous transluminal angioplasty.

###### 

An example of acute thrombotic occlusion of the external iliac artery (**A**), insertion and advancement of the Rotarex^®^ device (**B**), intermediate result (**C**), PTA (**D**), as well as revascularization angiogram following the successful mechanical thrombectomy/PTA/stent implantation (**E**).

**Abbreviation:** PTA, percutaneous transluminal angioplasty.

###### 

Number of patients where ABI had been determined

  ABI                Pre (prior to intervention)   Post (post-intervention)   1 month   3 months   6 months   12 months
  ------------------ ----------------------------- -------------------------- --------- ---------- ---------- -----------
  Rotarex^®^         95                            105                        46        49         40         33
  Lysis              15                            15                         6         9          7          8
  Rotarex^®^+lysis   16                            17                         9         8          6          5

**Abbreviation:** ABI, ankle-brachial index.

The authors are grateful to Dr Christian Stock (Institute for Medical Biometry and Informatics, University Hospital Heidelberg, Germany) for his statistical support and helpful manuscript suggestions. This work was supported by a grant from ab medica GmbH to E.B. for a Rotarex^®^ evaluation study.
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ABI

:   ankle-brachial index

ALI

:   acute limb ischemia

CLI

:   critical limb ischemia

PTA

:   percutaneous transluminal angioplasty

rtPA

:   recombinant tissue plasminogen activator

SFA

:   superficial femoral artery

![Kaplan--Meier curves representing overall survival (**A** and **B**) and amputation-free survival (**C** and **D**) of Rotarex^®^ (blue)-, lysis (green)-, and Rotarex^®^+lysis (red)-treated patients. The figure is subdivided into a population of noncritically ill (left panel) vs critically ill (right panel) patients. *P*-values are attributed to the corresponding subfigures.](dddt-11-1233Fig1){#f1-dddt-11-1233}

![Twelve-month freedom from target lesion revascularization, re-occlusion, or significant restenosis is presented as Kaplan--Meier primary (**A**) and secondary patency (**B**) curves. Rotarex^®^-treated patients are coded in blue, lysis-treated in green, and Rotarex^®^+lysis-treated in red. *P*-values are attributed to the corresponding subfigures.](dddt-11-1233Fig2){#f2-dddt-11-1233}

![ABI prior to (pre), immediately after (post), as well as 1, 3, 6, and 12 months after revascularization. Rotarex^®^-treated patients are identified in blue, lysis-treated patients in green, and Rotarex^®^+lysis-treated ones in red.\
**Abbreviation**: ABI, ankle-brachial index.](dddt-11-1233Fig3){#f3-dddt-11-1233}

###### 

Demographic characteristics of the study population in terms of age, gender, and weight

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                Rotarex^®^ (Straub Medical AG, Straubstrasse, Switzerland)   Lysis       Rotarex^®^+lysis                                          *P*-value
  ------------- ------------------------------------------------------------ ----------- --------------------------------------------------------- -----------------------------------------------------------
  Age (years)   67.5±11.4                                                    61.5±14.3   72.5±9.7                                                  R vs R+L[\*](#tfn1-dddt-11-1233){ref-type="table-fn"}\
                                                                                                                                                   R vs L ns\
                                                                                                                                                   L vs R+L[\*\*\*](#tfn3-dddt-11-1233){ref-type="table-fn"}

  Gender        M 63.1%                                                      M 64.3%     M 71.4%                                                   R vs R+L[\*\*](#tfn2-dddt-11-1233){ref-type="table-fn"}

  F 36.9%       F 35.7%                                                      F 29.4%     R vs L ns\                                                
                                                                                         L vs R+L[\*\*](#tfn2-dddt-11-1233){ref-type="table-fn"}   

  Weight (kg)   74.4±14.1                                                    76.2±14     80.7±10.9                                                 ns
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

*P*\<0.05,

*P*\<0.01, and

*P*\<0.001.

**Abbreviations:** M, male; F, female; R, Rotarex^®^; L, lysis; ns, nonsignificant.

###### 

Major comorbidities of the study population

                             Rotarex^®^                   Lysis                      Rotarex^®^+lysis
  -------------------------- ---------------------------- -------------------------- --------------------------
  Ischemic cardiac disease   44.5% (65/146)               39.3% (11/28)              46.4% (13/28)
  Arterial hypertension      75.3% (110/146)              78.6% (22/28)              78.6% (22/28)
  Diabetes mellitus          32.2% (47/146)               28.6% (8/28)               50% (14/28)
  Smoking                    63.7% (93/146)               60.7% (17/28)              67.9% (19/28)
  Kidney failure (III--V)    Stadium III 17.8% (26/146)   Stadium III 21.4% (6/28)   Stadium III 10.7% (3/28)
                             Stadium IV 3.4% (5/146)      Stadium IV 3.6% (1/28)     Stadium IV 10.7% (3/28)
                             Stadium V 2.1% (3/146)       Stadium V 0                Stadium V 0
  Hyperlipidemia             36.9% (54/146)               39.2% (11/28)              35.7% (10/28)

**Note:** *P*-values \>0.05.

###### 

Major lesions' characteristics and their distribution in different interventional groups

  ----------------------------------------------------------------------------------------------------------------------------------------
                             Rotarex^®^        Lysis           Rotarex^®^+lysis   *P*-value
  -------------------------- ----------------- --------------- ------------------ --------------------------------------------------------
  Native vessel              68.5% (100/146)   78.6% (22/28)   71.4% (20/28)      ns

  Bypass                     1.4% (2/146)      3.6% (1/28)     10.7% (3/28)       R vs R+L[\*](#tfn6-dddt-11-1233){ref-type="table-fn"}\
                                                                                  R vs L ns\
                                                                                  L vs R+L ns

  Calcification grade                                                             

   Low                       70.6% (103/146)   78.6% (22/28)   71.4% (20/28)      ns

   Moderate--severe          29.5% (43/146)    21.4% (6/28)    28.6% (8/28)       ns

  Thrombotic burden                                                               

   Low                       32.3% (50/146)    28.6% (8/28)    10.7% (3/28)       R vs R+L[\*](#tfn6-dddt-11-1233){ref-type="table-fn"}

   Moderate--severe          65.8% (96/146)    71.7% (20/28)   89.3% (25/28)      R vs L ns\
                                                                                  L vs R+L ns

  Length of occlusion (cm)                                                        

   \>10                      75.3% (110/146)   71.4% (20/28)   85.7% (24/28)      ns

   \<10                      24.7% (36/146)    28.6% (8/28)    14.3% (4/28)       ns

  Stent                      55.5% (80/146)    46.4% (13/28)   42.9% (12/28)      ns

  PTA                        73.9% (108/146)   71.4% (20/28)   78.6% (22/28)      ns
  ----------------------------------------------------------------------------------------------------------------------------------------

**Note:**

*P*\<0.05.

**Abbreviations:** ns, nonsignificant; R, Rotarex^®^; L, lysis; PTA, percutaneous transluminal angioplasty.

###### 

Target lesion localization for Rotarex^®^, lysis, and Rotarex^®^+lysis

  -----------------------------------------------------------------------------------------------------------------
                   Rotarex^®^   Lysis   Rotarex^®^+lysis   *P*-value
  ---------------- ------------ ------- ------------------ --------------------------------------------------------
  Iliac vessels    12.5%        28.6%   16.7%              ns

  SFA              69.3%        40%     52%                R vs R+L ns\
                                                           R vs L[\*\*](#tfn8-dddt-11-1233){ref-type="table-fn"}\
                                                           L vs R+L ns

  Below the knee   18.7%        31.4%   31.3%              ns
  -----------------------------------------------------------------------------------------------------------------

**Note:**

*P*\<0.01.

**Abbreviations:** ns, nonsignificant; R, Rotarex^®^; L, lysis; SFA, superficial femoral artery.

###### 

Major complications in the three intervention groups. Patients were additionally subdivided into critically ill (white space) and noncritically ill (gray space)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                Rotarex^®^     Lysis          Rotarex^®^+lysis                                            Total           *P*-value
  ----------------------------- -------------- -------------- ----------------------------------------------------------- --------------- -------------------------------------------------------------
  Major bleeding                3.6% (5/138)   22.2% (4/18)   0                                                           5.11% (9/176)   R vs L[\*](#tfn10-dddt-11-1233){ref-type="table-fn"}\
                                                                                                                                          R vs R+L ns\
                                                                                                                                          L vs R+L[\*](#tfn10-dddt-11-1233){ref-type="table-fn"}

                                0              10% (1/10)     25% (2/8)                                                   11.5% (3/26)    R vs L ns\
                                                                                                                                          R vs R+L[\*\*](#tfn11-dddt-11-1233){ref-type="table-fn"}\
                                                                                                                                          L vs R+L ns

  Aneurysma sp.                 2.9% (4/138)   0              0                                                           2.3% (4/176)    ns

                                0              0              12.5% (1/8)[\*](#tfn10-dddt-11-1233){ref-type="table-fn"}   3.8% (1/26)     ns

  AV-fistula                    0.7% (1/138)   0              0                                                           0.6% (1/176)    ns

                                0              0              0                                                           0               ns

  Compartment                   0              0              0                                                           0               ns

                                0              0              12.5% (1/8)                                                 3.8% (1/26)     R vs L ns\
                                                                                                                                          R vs R+L[\*](#tfn10-dddt-11-1233){ref-type="table-fn"}\
                                                                                                                                          L vs R+L[\*](#tfn10-dddt-11-1233){ref-type="table-fn"}

  Hospital length stay (days)   1.4±0.9        4.6±3          4.4±1.8                                                     --              R vs L[\*\*\*](#tfn12-dddt-11-1233){ref-type="table-fn"}\
                                                                                                                                          R vs R+L[\*\*\*](#tfn12-dddt-11-1233){ref-type="table-fn"}\
                                                                                                                                          L vs R+L ns

                                21.7±34.4      13.3±4.5       18.3±9.36                                                   --              ns
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

*P*\<0.05,

*P*\<0.01, and

*P*\<0.001. Data are presented as mean ± standard deviation or % (n/N).

**Abbreviations:** R, Rotarex^®^; L, lysis; ns, nonsignificant; AV, arteriovenous.
